Atul J. Agrawal

FDA investigator

Appears on 5 documents from 2011 to 2018, mostly at sites in New Jersey. Most often cites production record review (21 CFR 211.192).

5
Documents on file
11.3
Observations per 483
2011
First seen
2018
Most recent

What they cite most

From 33 observations

Activity by year

2011: 3, 2018: 2

Where

New Jersey 4 · West Virginia 1

Is Atul J. Agrawal coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

5 documents, newest first
FirmOpen
483 Akorn Inc.Aug 30, 2018 · Somerset, New Jersey
483 Mylan Pharmaceuticals Inc.Apr 12, 2018 · Morgantown, West Virginia
Response Jacobus Pharmaceutical Company, Inc.Mar 9, 2011 · Princeton, New Jersey
Amended 483 Jacobus Pharmaceutical Company, Inc.Feb 18, 2011 · Plainsboro, New Jersey
EIR Jacobus Pharmaceutical Company, Inc.Feb 18, 2011 · Plainsboro, New Jersey

About this profile

What does Atul J. Agrawal inspect?

Atul J. Agrawal appears on 5 documents on file covering 3 sites, mostly in New Jersey.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.67 and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Atul J. Agrawal is dated Aug 30, 2018.